• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人调节性 T 细胞缺乏环磷酰胺外排转运体 ABCB1,因此更容易受到环磷酰胺诱导的细胞凋亡。

Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis.

机构信息

Immunobiology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland.

出版信息

Eur J Immunol. 2014 Dec;44(12):3614-20. doi: 10.1002/eji.201444879. Epub 2014 Oct 27.

DOI:10.1002/eji.201444879
PMID:25251877
Abstract

ATP-binding cassette (ABC) transporters, including ABC-transporter B1 (ABCB1), extrude drugs, metabolites, and other compounds (such as mitotracker green (MTG)) from cells. Susceptibility of CD4(+) regulatory T (Treg) cells to the ABCB1-substrate cyclophosphamide (CPA) has been reported. Here, we characterized ABCB1 expression and function in human CD4(+) T-cell subsets. Naïve, central memory, and effector-memory CD4(+) T cells, but not Treg cells, effluxed MTG in an ABCB1-dependent manner. In line with this, ABCB1 mRNA and protein was expressed by nonregulatory CD4(+) T-cell subsets, but not Treg cells. In vitro, the ABCB1-substrate CPA was cytotoxic for Treg cells at a 100-fold lower dose than for nonregulatory counterparts, and, inversely, verapamil, an inhibitor of ABC transporters, increased CPA-toxicity in nonregulatory CD4(+) T cells but not Treg cells. Thus, Treg cells lack expression of ABCB1, rendering them selectively susceptible to CPA. Our findings provide mechanistic support for therapeutic strategies using CPA to boost anti-tumor immunity by selectively depleting Treg cells.

摘要

三磷酸腺苷结合盒(ABC)转运蛋白,包括 ABC 转运蛋白 B1(ABCB1),将药物、代谢物和其他化合物(如米托蒽醌绿(MTG))从细胞中排出。已经报道了 CD4(+) 调节性 T(Treg)细胞对 ABCB1 底物环磷酰胺(CPA)的敏感性。在这里,我们描述了 ABCB1 在人 CD4(+) T 细胞亚群中的表达和功能。幼稚、中央记忆和效应记忆 CD4(+) T 细胞,但不是 Treg 细胞,以 ABCB1 依赖性方式排出 MTG。与此一致,非调节性 CD4(+) T 细胞亚群表达 ABCB1 mRNA 和蛋白,但 Treg 细胞不表达。在体外,ABCB1 底物 CPA 对 Treg 细胞的细胞毒性比非调节性对照细胞低 100 倍,相反,ABC 转运蛋白抑制剂维拉帕米增加了非调节性 CD4(+) T 细胞而非 Treg 细胞中 CPA 的细胞毒性。因此,Treg 细胞缺乏 ABCB1 的表达,使其对 CPA 具有选择性敏感性。我们的发现为使用 CPA 通过选择性耗尽 Treg 细胞来增强抗肿瘤免疫的治疗策略提供了机制支持。

相似文献

1
Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis.人调节性 T 细胞缺乏环磷酰胺外排转运体 ABCB1,因此更容易受到环磷酰胺诱导的细胞凋亡。
Eur J Immunol. 2014 Dec;44(12):3614-20. doi: 10.1002/eji.201444879. Epub 2014 Oct 27.
2
iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity.iNOS 在 CD4+T 细胞中的表达通过抑制 TGFβ1 来限制 Treg 的诱导:联合 iNOS 抑制和 Treg 耗竭揭示内源性抗肿瘤免疫。
Clin Cancer Res. 2014 Dec 15;20(24):6439-51. doi: 10.1158/1078-0432.CCR-13-3409. Epub 2014 Oct 2.
3
Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels.低剂量环磷酰胺通过降低细胞内 ATP 水平来选择性耗竭 CD4+CD25+Foxp3+调节性 T 细胞。
Cancer Res. 2010 Jun 15;70(12):4850-8. doi: 10.1158/0008-5472.CAN-10-0283. Epub 2010 May 25.
4
Low dose cyclophosphamide: Mechanisms of T cell modulation.低剂量环磷酰胺:T 细胞调节的机制。
Cancer Treat Rev. 2016 Jan;42:3-9. doi: 10.1016/j.ctrv.2015.11.005. Epub 2015 Nov 22.
5
Cyclophosphamide inhibits the generation and function of CD8(+) regulatory T cells.环磷酰胺抑制 CD8(+)调节性 T 细胞的生成和功能。
Hum Immunol. 2012 Mar;73(3):207-13. doi: 10.1016/j.humimm.2011.12.020. Epub 2012 Jan 14.
6
Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.两种起源相似的肝癌细胞系对靶向调节性或效应性T细胞的免疫疗法的不同反应。
Oncol Rep. 2007 May;17(5):1269-73.
7
Role of interferon regulatory factor 1 in governing Treg depletion, Th1 polarization, inflammasome activation and antitumor efficacy of cyclophosphamide.干扰素调节因子 1 在调节 Treg 耗竭、Th1 极化、炎症小体激活和环磷酰胺抗肿瘤疗效中的作用。
Int J Cancer. 2018 Mar 1;142(5):976-987. doi: 10.1002/ijc.31083. Epub 2017 Oct 16.
8
Effects of cyclophosphamide and soluble tumor-associated antigens on lymphoid infiltration, proliferative activity and rate of apoptosis in chemically-induced rat mammary tumors.环磷酰胺和可溶性肿瘤相关抗原对化学诱导的大鼠乳腺肿瘤中淋巴细胞浸润、增殖活性及凋亡率的影响
In Vivo. 2002 Sep-Oct;16(5):287-92.
9
Response of the immune system of mammary tumor-bearing rats to cyclophosphamide and soluble low-molecular-mass tumor-associated antigens: rate of lymphoid infiltration and distribution of T lymphocytes in tumors.荷乳腺肿瘤大鼠免疫系统对环磷酰胺和可溶性低分子量肿瘤相关抗原的反应:肿瘤中淋巴细胞浸润率及T淋巴细胞分布
Int J Mol Med. 2002 Apr;9(4):425-30.
10
High-dose cyclophosphamide-mediated anti-tumor effects by the superior expansion of CD44(high) cells after their selective depletion.高剂量环磷酰胺通过选择性耗竭后 CD44(high) 细胞的优势扩增来发挥抗肿瘤作用。
Immunobiology. 2010 Mar;215(3):182-93. doi: 10.1016/j.imbio.2009.01.010. Epub 2009 May 22.

引用本文的文献

1
Cancer Immunotherapy in Combination with Radiotherapy and/or Chemotherapy: Mechanisms and Clinical Therapy.癌症免疫疗法与放疗和/或化疗联合应用:作用机制与临床治疗
MedComm (2020). 2025 Aug 31;6(9):e70346. doi: 10.1002/mco2.70346. eCollection 2025 Sep.
2
Calcium Electrochemotherapy and Challenges in Combined Treatment with Dendritic Cell Vaccination.钙电化学疗法及与树突状细胞疫苗联合治疗中的挑战
Pharmaceutics. 2025 Jun 21;17(7):804. doi: 10.3390/pharmaceutics17070804.
3
PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies.
PD-1/PD-L1 免疫检查点阻断在乳腺癌中的研究进展与增敏策略。
Mol Cancer. 2024 Nov 29;23(1):266. doi: 10.1186/s12943-024-02176-8.
4
Towards targeting the breast cancer immune microenvironment.针对乳腺癌免疫微环境。
Nat Rev Cancer. 2024 Aug;24(8):554-577. doi: 10.1038/s41568-024-00714-6. Epub 2024 Jul 5.
5
Enhancing in situ cancer vaccines using delivery technologies.利用递送技术增强原位癌症疫苗。
Nat Rev Drug Discov. 2024 Aug;23(8):607-625. doi: 10.1038/s41573-024-00974-9. Epub 2024 Jul 1.
6
Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis.肝动脉灌注化疗联合卡瑞利珠单抗加瑞戈非尼治疗伴有门静脉癌栓的肝细胞癌:一项多中心倾向评分匹配分析。
Hepatol Int. 2024 Aug;18(4):1286-1298. doi: 10.1007/s12072-024-10672-8. Epub 2024 May 8.
7
Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis.肝动脉灌注化疗(HAIC)联合抗 PD-1 治疗与 HAIC 单药治疗晚期肝细胞癌的疗效和安全性:一项多中心倾向评分匹配分析。
Cancer Med. 2024 Jan;13(1):e6836. doi: 10.1002/cam4.6836. Epub 2024 Jan 9.
8
In Doxorubicin-Adapted Hodgkin Lymphoma Cells, Acquiring Multidrug Resistance and Improved Immunosuppressive Abilities, Doxorubicin Activity Was Enhanced by Chloroquine and GW4869.在多柔比星适应的霍奇金淋巴瘤细胞中,获得多药耐药性和改善的免疫抑制能力后,氯喹和 GW4869 增强了多柔比星的活性。
Cells. 2023 Nov 29;12(23):2732. doi: 10.3390/cells12232732.
9
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations.免疫疗法联合治疗方法:机制、生物标志物和临床观察。
Nat Rev Immunol. 2024 Jun;24(6):399-416. doi: 10.1038/s41577-023-00973-8. Epub 2023 Dec 6.
10
MDR1-EXPRESSING CD4 T CELLS WITH TH1.17 FEATURES RESIST TO NEOADJUVANT CHEMOTHERAPY AND ARE ASSOCIATED WITH BREAST CANCER CLINICAL RESPONSE.表达 MDR1 的 CD4 T 细胞具有 TH1.17 特征,对新辅助化疗有耐药性,并与乳腺癌临床反应相关。
J Immunother Cancer. 2023 Nov;11(11). doi: 10.1136/jitc-2023-007733.